| Astellas Seals the Deal With OSI After Rocky Courtship The Burrill Report submits: By Michael FitzhughAstellas Pharma (ALPMF.PK), Japan's second-largest drugmaker, is paying $4 billion for OSI Pharmecuticals (OSIP) and its profitable cancer medicine, Tarceva. The pricey victory is a triple-win for Astellas, likely to bolster its revenue, geographic base, and pipeline. Complete Story » seekingalpha.com |
Amgen's 15-Year Effort to Build a Blockbuster Pays Off The Burrill Report submits: Amgen’s (AMGN) denosumab, its treatment for osteoporosis, has won approval in both Europe and the United States. Marketed under the name Prolia, analysts forecast sales will approach $1 billion in 2011 and EvaluatePharma thinks that could grow to $5.3 billion by 2016.We spoke to Dave Lacey, senior vice president and head of research for Amgen, about the long road travelled to bring Prolia to market, why the discovery and development of new drugs like it remains so difficult, and what other interesting therapies might be working their way through Amgen’s deep pipeline.Complete Story » seekingalpha.com |
Lexicon Pharmaceuticals Incorporated Q2 2010 Earnings Call Transcript Lexicon Pharmaceuticals Incorporated (LXRX)Q2 2010 Earnings CallAugust 9, 2010 11:01 amComplete Story » seekingalpha.com |
Stem-Cell Plaintiffs Cite Ethical Factors The two scientists behind the lawsuit that has temporarily blocked federal funding for embryonic stem-cell research said they were motivated by ethical objections to destroying human embryos for medical research. online.wsj.com |
Detecting More Upside Potential for EXACT Sciences Mike Havrilla submits:With shares of EXACT Sciences (EXAS) pulling back from multi-year highs in the low $9s back to the low-mid $7s as I write this article, I am adding to my long stock position ahead of the validation study results to be presented next week. (Click here for my recent article on the merger of my site with BioRunUp.com, providing investors and traders with more resources to profit from FDA and clinical trial binary events.)Next-Generation (V3), Stool DNA (sDNA) Based Colorectal Cancer (CRC) Diagnostic Test Kit Complete Story » seekingalpha.com |